⌘K
OverviewStock screenerAnalyst actionsTicker roomsCalendar
MarketsInvestorsSign in
StockUnited StatesNasdaqCM

DNTH

Dianthus Therapeutics, Inc.

Healthcare · Biotechnology

76.78USD

-1.7500 (-2.23%)

Alert
DescriptionHistoricalFinancialsRelative ValueResearchNewsCommunityRoomOptionsPrice Chart ↗Fundamental Chart ↗
ProfileRatiosRevenue & EPS
Reading financial statements from SEC filings…
A first visit to a security takes a few seconds.

Community sentiment

Not enough data yet

A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.

Sign in to share your take on DNTH.

Members' own stated views, weighted by account age and track record on this site (simulated portfolios and calls). Not a forecast or a price signal. How this is worked out
  • Only members whose accounts are at least 14 days old and who have a track record on this site (simulated portfolios and calls) count, and bots never do. A take from anyone else is saved and starts to count the day they qualify.
  • A take fades: it counts half as much after 7 days and drops out after 30.
  • Members with a strong record count more. Everyone else counts together for a capped share, so many accounts cannot outweigh a few strong ones.
  • Nothing is shown until 5 qualifying members have taken part, 2 of them with a strong record. It stays an early read until 3 have one and the sample is large enough.
  • Until 20 members have taken part the marker only says bullish, bearish or mixed, at a fixed spot, and the number of members is given as a band, not a count.
  • The reading is refreshed about every 30 minutes, so a take you have just made will not move it straight away.
  • Your own take is private: only the totals are shown, and never who said what.
1)

Comparable Revenue

EM »

Revenue

 

 

QuarterlyAnnual
Reported
(USD)202220232024202520262027
FY—2.8M6.2M2.0M1.9M1.8M
Q1——874.0K1.2M——
Q2——1.9M193.0K——
Q31.2M924.0K2.2M396.0K366.4K—
Q4—457.0K*1.3M*284.0K*281.2K—
2)

Comparable Earnings Per Share

EM »

Revenue

 

 

QuarterlyAnnual
Reported
(USD)202220232024202520262027
FY-.905-1.41-2.55-4.20-3.81-4.61
Q1-.726-.225-.540-.820-.850—
Q2-.540-.354-.510-.880-.900—
Q3-.247-.630-.740-.970-.949—
Q4-.321*

Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.

3)

Revenue to Profit Conversion

Revenue to net income

 

 

QuarterlyAnnual
Level
-.342*
-.854*
-1.67*
-1.11
—
4)

Debt Level and Coverage

Debt level and coverage

 

 

QuarterlyAnnual
Debt